CareSens N 30G lancets x 100

Product Information

Medicines suitable for routine use within primary care. Initiation and maintenance of prescribing by Specialists, GPs and other qualified clinicians. Training on the correct use, storage and recording of the readings should be provided by the issuing clinician Pioglitazone should not be used in people who have heart failure or who are at higher risk of fracture. Continue Pioglitazone therapy only if there is a reduction of ≥0.5 percentage points in HbA1c in 6 months. Monitor for liver toxicity. There is risk of bladder cancer with pioglitazone. Do not use in active bladder cancer or a past history of bladder cancer, or in those who have uninvestigated macroscopic haematuria. Assess risks for bladder cancer after 3-6months of starting pioglitazone. Refer to current BNF for full contraindications and interactions The managed introduction of biosimilar Insulin Glargine (Semglee®▼) for patients with Type 2 Diabetes

MHRA: Canagliflozin (Invokana, Vokanamet): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients

Prescribe by brand (Saxenda ®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist. For the treatment of patients with Type 1 or Type 2 diabetes who have nocturnal hypoglycaemia and are on ≥80 units of basal analogue insulin (e.g. Abasaglar®, Lantus®, Levemir® or Semglee®) Restricted use: Meter is restricted for use in patients with needle phobia, paediatrics, visual impairments and physicial impairments requiring single-handed use

See DMMAG Type 2 Diabetes Mellitus - Guideline for the choice of oral and non-insulin antidiabetic agents for adults You can use blood samples taken your fingertip, palm or forearm. A small sample of blood is required and your result is displayed in less than 5 seconds. SLGT2 inhibitors are not to beused inprimary care for type 1 diabetes until further local guidance becomes available

Thin lancets and 1,000 test memory

It should be swallowed whole with a sip of water (up to half a glass of water equivalent to 120 ml). for treating chronic heart failure with reduced ejection fraction as per NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction MHRA Alert: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019) The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management servicewith a commercial agreement in place.

MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness For the treatment of patients with Type 2 diabetes who have nocturnal / severe hypoglycaemia or those with recurrent hypoglycaemic episodes requiring hospital admission

Sample loading – avoid spoiled tests

For usein pregnant women with either gestational diabetes or pre-existing diabetes, after other insulins have been tried and failed to reach post-prandial glucose targets. NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes Firmly insert a new lancet into the lancet holder. Hold the lancet firmly. Gently twist to pull off the protective disk. Save disk to recap lancet after use. Replace lancet device tip.